Healthcare / BiotechnologyTaipei Exchange
$60.20
+2.00 (+3.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-196.5M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-111.9%
↓Gross Margin
16.6%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+66.8%
FCF CAGR
—
FCF margin
-4687.8%
FCF / Net income
0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.6M · net income $-357.9M · FCF $-354.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.6M | $7.6M | $96.4M | $143.5M | $1.6M |
| Net Income | $-357.9M | $-357.9M | $-354.0M | $-329.2M | $-236.7M |
| EBITDA | $-311.1M | $-311.1M | $-307.3M | $-252.0M | $-194.6M |
| EPS | — | — | -3.78 | -4.22 | -3.58 |
| Gross Margin | 16.6% | 16.6% | 9.2% | 12.8% | 68.6% |
| Operating Margin | -4891.0% | -4891.0% | -373.4% | -187.2% | -14790.6% |
| Net Margin | -4738.7% | -4738.7% | -367.0% | -229.4% | -14554.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.08 | 0.07 | — |
| Current Ratio | 3.60 | 3.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-354.0M | $-354.0M | $-196.5M | $-79.6M | $-191.5M |
| Returns | |||||
| ROE | -111.9% | -111.9% | -53.5% | -35.6% | -46.4% |
| Valuation | |||||
| P/B | 17.84 | 17.84 | 4.97 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -92.2% | -92.2% | -32.8% | 8727.2% | — |
| EPS Growth | — | — | 10.4% | -17.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+150.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.78 → n/d
Residual
+150.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.